Frank I. Navetta

Combined Accelerated Tissue-Plasminogen Activator and Platelet Glycoprotein IIb/IIIa Integrin Receptor Blockade With Integrilin in Acute Myocardial Infarction

E. Magnus Ohman, Neal S. Kleiman, Gerald M. Gacioch et al. · Circulation · 1997 · 380 citations

Point-of-Care Measured Platelet Inhibition Correlates With a Reduced Risk of an Adverse Cardiac Event After Percutaneous Coronary Intervention

Steven R. Steinhubl, J. David Talley, Gregory A. Braden et al. · Circulation · 2001 · 358 citations

Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Platelet Integrin Glycoprotein IIb/IIIa Blocker Integrelin in Elective Coronary Intervention

James E. Tcheng, Robert A. Harrington, Kandice Kottke‐Marchant et al. · Circulation · 1995 · 280 citations

Effects of Integrelin, a Platelet Glycoprotein IIb/IIIa Receptor Antagonist, in Unstable Angina

Steven P. Schulman, Pascal J. Goldschmidt‐Clermont, Eric J. Topol et al. · Circulation · 1996 · 108 citations

Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery

James D. Boehrer, Dean J. Kereiakes, Frank I. Navetta et al. · The American Journal of Cardiology · 1994 · 100 citations

Thrombopoiesis, Thrombosis, Percutaneous Coronary Intervention +11